Hobbs Group Advisors LLC Has $214,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Hobbs Group Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 25.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,481 shares of the company’s stock after acquiring an additional 305 shares during the quarter. Hobbs Group Advisors LLC’s holdings in Johnson & Johnson were worth $214,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Biondo Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.2% in the fourth quarter. Biondo Investment Advisors LLC now owns 58,674 shares of the company’s stock valued at $8,485,000 after purchasing an additional 1,289 shares in the last quarter. Allstate Corp lifted its holdings in shares of Johnson & Johnson by 4,270.3% during the 4th quarter. Allstate Corp now owns 71,236 shares of the company’s stock valued at $10,302,000 after buying an additional 69,606 shares during the last quarter. RiverFront Investment Group LLC grew its position in Johnson & Johnson by 9.4% in the fourth quarter. RiverFront Investment Group LLC now owns 6,280 shares of the company’s stock worth $908,000 after acquiring an additional 541 shares in the last quarter. Alerus Financial NA increased its position in Johnson & Johnson by 2.0% during the fourth quarter. Alerus Financial NA now owns 54,185 shares of the company’s stock worth $7,836,000 after buying an additional 1,058 shares during the last quarter. Finally, Vertex Planning Partners LLC raised its stake in shares of Johnson & Johnson by 3.4% in the 4th quarter. Vertex Planning Partners LLC now owns 5,390 shares of the company’s stock valued at $780,000 after acquiring an additional 179 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Stock Up 0.3 %

Shares of Johnson & Johnson stock opened at $163.63 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The business’s 50 day simple moving average is $158.68 and its 200 day simple moving average is $156.21. The firm has a market cap of $394.32 billion, a PE ratio of 24.61, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the previous year, the firm posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.